Payment overview · 2025
General Payments
$1,078.69
37 reported records · 19 companies
Healthcare provider profile · identity verified
David M Gilbert, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · HANOVER, PA · NPI 1427024496
Verified facts
What the public records show
CMS Open Payments records show David M Gilbert, DO received $1,078.69 in general payments during 2025 across 37 reported records.
Reflow Medical Inc accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Wegovy.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $216.69 | 20.1% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $136.08 | 12.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $107.41 | 10.0% | 3 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $69.66 | 6.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.16 | 5.7% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $58.20 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.45 | 5.3% | 3 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $55.91 | 5.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $53.84 | 5.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.55 | 4.8% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $40.69 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.63 | 3.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.30 | 3.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.24 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.26 | 1.8% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $16.26 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.18 | 1.5% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $14.61 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.57 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,078.69 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $136.08 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $93.53 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $61.16 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $58.20 | 2 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $57.45 | 3 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $55.91 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $53.84 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.55 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $40.69 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.30 | 2 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Becton, Dickinson and Company | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| URGOK2 Normalized: urgok2 |
Device | Urgo Medical North America, LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 279 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
279 | 73 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 483 | 149 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 114 |
| Clopidogrel | Clopidogrel Bisulfate | 293 | 93 |
| Eliquis | Apixaban | 279 | 73 |
| Carvedilol | Carvedilol | 277 | 77 |
| Torsemide | Torsemide | 275 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 54 |
| Lisinopril | Lisinopril | 169 | 50 |
| Spironolactone | Spironolactone | 155 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 38 |
| Xarelto | Rivaroxaban | 105 | 29 |
| Entresto | Sacubitril/Valsartan | 77 | 18 |
| Irbesartan | Irbesartan | 76 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 24 |
| Warfarin Sodium | Warfarin Sodium | 69 | 23 |
| Metolazone | Metolazone | 65 | 25 |
| Losartan Potassium | Losartan Potassium | 63 | 26 |
| Sotalol | Sotalol Hcl | 62 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 17 |
| Flecainide Acetate | Flecainide Acetate | 56 | 15 |
| Atenolol | Atenolol | 54 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Chlorthalidone | Chlorthalidone | 44 | 16 |
| Brilinta | Ticagrelor | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Nitroglycerin | Nitroglycerin | 33 | 20 |
| Tramadol Hcl | Tramadol Hcl | 26 | 15 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Pacerone | Amiodarone Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,078.69 · 37 records | Reflow Medical Inc | CAMZYOS, CAPLYTA, Cologuard Collection Kit, Crosser IQ, DIAMONDBACK PERIPHERAL, ELIQUIS, FUROSCIX, Kerendia, LEQVIO, LUTONIX Drug Coated Balloon, NUZYRA, ORGOVYX, Optimizer, Repatha, RotarexS 6 F x 135 cm, TMC NANOPLASTY SYSTEM, The Cologuard Plus Collection Kit, URGOK2, VENASEAL, Varithena Administration Pack, Venovo, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error